Insider Selling: Axon Enterprise (NASDAQ:AXON) CFO Sells 2,000 Shares of Stock

Axon Enterprise, Inc (NASDAQ:AXON) CFO Brittany Bagley sold 2,000 shares of the business’s stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $580.00, for a total value of $1,160,000.00. Following the transaction, the chief financial officer owned 103,501 shares of the company’s stock, valued at $60,030,580. This represents a 1.90% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Brittany Bagley also recently made the following trade(s):

• On Monday, November 10th, Brittany Bagley sold 2,500 shares of Axon Enterprise stock. The shares were sold at an average price of $610.00, for a total value of $1,525,000.00.
• On Monday, September 29th, Brittany Bagley sold 5,000 shares of Axon Enterprise stock. The shares were sold at an average price of $713.88, for a total transaction of $3,569,400.00.
• On Monday, September 15th, Brittany Bagley sold 870 shares of Axon Enterprise stock. The stock was sold at an average price of $773.25, for a total transaction of $672,727.50.

Axon Enterprise Stock Performance

Shares of AXON stock traded down $16.75 during trading hours on Friday, reaching $564.28. The stock had a trading volume of 924,614 shares, compared to its average volume of 711,618. The firm has a market capitalization of $44.53 billion, a PE ratio of 178.57, a price-to-earnings-growth ratio of 130.54 and a beta of 1.40. The firm has a 50-day simple moving average of $626.97 and a 200-day simple moving average of $715.54. Axon Enterprise, Inc has a twelve month low of $469.24 and a twelve month high of $885.91. The company has a debt-to-equity ratio of 0.57, a current ratio of 3.12 and a quick ratio of 2.89.

Axon Enterprise (NASDAQ:AXON) last posted its earnings results on Wednesday, November 5th. The biotechnology company reported $1.17 EPS for the quarter, missing the consensus estimate of $1.63 by ($0.46). Axon Enterprise had a return on equity of 4.29% and a net margin of 10.05%.The firm had revenue of $710.64 million during the quarter, compared to the consensus estimate of $704.83 million. During the same quarter last year, the company posted $1.45 EPS. Axon Enterprise’s revenue for the quarter was up 30.6% on a year-over-year basis. As a group, equities analysts forecast that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Institutional Investors Weigh In On Axon Enterprise

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Stone House Investment Management LLC acquired a new position in shares of Axon Enterprise in the 3rd quarter worth $29,000. New Millennium Group LLC acquired a new position in shares of Axon Enterprise in the 3rd quarter valued at $29,000. Banque Transatlantique SA purchased a new position in Axon Enterprise in the 1st quarter worth about $31,000. Flaharty Asset Management LLC acquired a new stake in Axon Enterprise during the 1st quarter worth about $33,000. Finally, Hemington Wealth Management lifted its stake in Axon Enterprise by 70.8% during the second quarter. Hemington Wealth Management now owns 41 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 17 shares in the last quarter. Institutional investors and hedge funds own 79.08% of the company’s stock.

Analyst Upgrades and Downgrades

AXON has been the topic of a number of recent analyst reports. Weiss Ratings restated a “hold (c-)” rating on shares of Axon Enterprise in a research note on Monday. Needham & Company LLC reissued a “buy” rating and set a $870.00 target price on shares of Axon Enterprise in a research note on Wednesday, September 24th. Cowen restated a “buy” rating on shares of Axon Enterprise in a research report on Wednesday, November 5th. JMP Securities reiterated a “market outperform” rating and issued a $825.00 price objective on shares of Axon Enterprise in a report on Monday, September 29th. Finally, Barclays lowered their price objective on shares of Axon Enterprise from $861.00 to $702.00 and set an “overweight” rating on the stock in a research note on Thursday, November 6th. Fourteen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $815.00.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.